Opportunities for immunotherapy in childhood acute myeloid leukemia

被引：36

作者：

Lamble, Adam J. ^{[1
,2
]}

Tasian, Sarah K. ^{[3
,4
,5
,6
]}

机构：

[1] Seattle Childrens Hosp, Div Hematol Oncol, Seattle, WA USA

[2] Univ Washington, Sch Med, Seattle, WA USA

[3] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA

[4] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA

[5] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA

[6] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

BLOOD ADVANCES | 2019年 / 3卷 / 22期

基金：

美国国家卫生研究院;

关键词：

STEM-CELL TRANSPLANTATION; ANTIBODY-DRUG CONJUGATE; GEMTUZUMAB OZOGAMICIN; PEDIATRIC-PATIENTS; T-CELLS; TRIAL; AML; SURVIVAL; THERAPY; RISK;

D O I：

10.1182/bloodadvances.2019000357

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Clinical outcomes for children with acute myeloid leukemia (AML) have improved minimally during the past 4 decades despite maximally intensive chemotherapy, hematopoietic stem cell transplantation, and optimized supportive care. Chemoresistance and relapse remain major sources of childhood cancer-associated mortality and highlight the need for alternative treatment approaches. The remarkable recent success of humoral and cellular immunotherapies in children and adults with relapsed/refractory B-acute lymphoblastic leukemia has inspired hope for similar accomplishments in patients with AML. However, unique challenges exist, including the biologic and immunophenotypic heterogeneity of childhood AML and the significant potential for on-target/off-tumor immunotherapeutic toxicity due to target antigen expression on nonmalignant cells. This article reviews the current landscape of antibody-based and cellular immunotherapies under current clinical evaluation with an emphasis on active or soon-to-open phase 1 trials for children with relapsed/refractory AML.

引用

页码：3750 / 3758

页数：9

共 56 条

[1] Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges [J].

Alfayez, Mansour ;

Borthakur, Gautam .

EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (05) :373-389

[2]

Alonzo TA, 2013, BLOOD, V122, P612

[3]

[Anonymous], 2017, BLOOD S1

[4] Effect of intensification of induction II chemotherapy and liberalization of stem cell donor source on outcome for children with high risk acute myeloid leukemia: A report from the Children's Oncology Group. [J].

Aplenc, Richard ;

Sung, Lillian ;

Pollard, Jessica Anne ;

Brodersen, Lisa ;

Loken, Michael ;

Gerbing, Robert B. ;

Getz, Kelly D. ;

Meshinchi, Soheil ;

Woods, William G. ;

Kolb, E. Anders ;

Alonzo, Todd Allen ;

Gamis, Alan S. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[5] EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia [J].

Balgobind, B. V. ;

Lugthart, S. ;

Hollink, I. H. ;

Arentsen-Peters, S. T. J. C. M. ;

van Wering, E. R. ;

de Graaf, S. S. N. ;

Reinhardt, D. ;

Creutzig, U. ;

Kaspers, G. J. L. ;

de Bont, E. S. J. M. ;

Stary, J. ;

Trka, J. ;

Zimmermann, M. ;

Beverloo, H. B. ;

Pieters, R. ;

Delwel, R. ;

Zwaan, C. M. ;

van den Heuvel-Eibrink, M. M. .

LEUKEMIA, 2010, 24 (05) :942-949

[6]

Berrien-Elliott MM, 2018, BLOOD S, V132, pSCI8

[7] The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions (vol 24, pg 103, 2018) [J].

Bolouri, Hamid ;

Farrar, Jason E. ;

Triche, Timothy, Jr. ;

Ries, Rhonda E. ;

Lim, Emilia L. ;

Alonzo, Todd A. ;

Ma, Yussanne ;

Moore, Richard ;

Mungall, Andrew J. ;

Marra, Marco A. ;

Zhang, Jinghui ;

Ma, Xiaotu ;

Liu, Yu ;

Liu, Yanling ;

Auvil, Jaime M. Guidry ;

Davidsen, Tanja M. ;

Gesuwan, Patee ;

Hermida, Leandro C. ;

Salhia, Bodour ;

Capone, Stephen ;

Ramsingh, Giridharan ;

Zwaan, Christian Michel ;

Noort, Sanne ;

Piccolo, Stephen R. ;

Kolb, E. Anders ;

Gamis, Alan S. ;

Smith, Malcolm A. ;

Gerhard, Daniela S. ;

Meshinchi, Soheil .

NATURE MEDICINE, 2018, 24 (04) :526-526

[8] CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping [J].

Bras, Anne E. ;

de Haas, Valerie ;

van Stigt, Arthur ;

Jongen-Lavrencic, Mojca ;

Beverloo, H. Berna ;

te Marvelde, Jeroen G. ;

Zwaan, C. Michel ;

van Dongen, Jacques J. M. ;

Leusen, Jeanette H. W. ;

van der Velden, Vincent H. J. .

CYTOMETRY PART B-CLINICAL CYTOMETRY, 2019, 96 (02) :134-142

[9] A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group [J].

Brodersen, L. Eidenschink ;

Alonzo, T. A. ;

Menssen, A. J. ;

Gerbing, R. B. ;

Pardo, L. ;

Voigt, A. P. ;

Kahwash, S. B. ;

Hirsch, B. ;

Raimondi, S. ;

Gamis, A. S. ;

Meshinchi, S. ;

Loken, M. R. .

LEUKEMIA, 2016, 30 (10) :2077-2080

[10]

Budde L, 2017, BLOOD, V130

← 1 2 3 4 5 6 →